Loading...
Market
What will be Lymphir's market share in the cutaneous T-cell lymphoma therapy market by December 31, 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market research reports and industry analysis
Story
Citius Pharmaceuticals Gains FDA Approval for Lymphir with Boxed Warning
Aug 8, 2024, 01:30 PM
Citius Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for its blood cancer therapy, Lymphir (denileukin diftitox-cxdl), aimed at treating adults with relapsed or refractory cutaneous T-cell lymphoma. This approval marks a significant milestone for Citius as it secures its first FDA approval. Lymphir is designed for patients who have undergone at least one prior treatment. The FDA's decision includes a boxed warning, highlighting potential risks associated with the therapy. The approval is expected to provide a new therapeutic option for patients with limited treatment choices.
View original story
Similar markets
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 5% • 25%
5% - 10% • 25%
10% - 15% • 25%
More than 15% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than 10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%